vs
Side-by-side financial comparison of CG Oncology, Inc. (CGON) and YXT.COM GROUP HOLDING Ltd (YXT). Click either name above to swap in a different company.
YXT.COM GROUP HOLDING Ltd is the larger business by last-quarter revenue ($3.1M vs $2.3M, roughly 1.4× CG Oncology, Inc.). YXT.COM GROUP HOLDING Ltd runs the higher net margin — 12.9% vs -1779.0%, a 1791.9% gap on every dollar of revenue.
CG Oncology, Inc. is a clinical-stage biotechnology company focused on developing innovative targeted immunotherapies for urological cancers including non-muscle invasive bladder cancer. It primarily operates in the U.S. market, advancing pipeline candidates to address unmet medical needs for patients with limited treatment options.
YXT.COM GROUP HOLDING Ltd is a leading digital learning solution provider operating primarily in the Chinese market. It offers corporate learning management systems, customized training content, and integrated talent development services for enterprise, educational institution and public sector clients across industries.
CGON vs YXT — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2024
| Metric | | |
|---|---|---|
| Revenue | $2.3M | $3.1M |
| Net Profit | $-41.3M | $405.6K |
| Gross Margin | — | 61.1% |
| Operating Margin | -2097.3% | -44.3% |
| Net Margin | -1779.0% | 12.9% |
| Revenue YoY | 409.2% | — |
| Net Profit YoY | -29.9% | — |
| EPS (diluted) | $-0.52 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.3M | — | ||
| Q3 25 | $1.7M | — | ||
| Q2 25 | $0 | — | ||
| Q4 24 | $456.0K | — | ||
| Q2 24 | — | $3.1M | ||
| Q1 24 | $529.0K | — |
| Q4 25 | $-41.3M | — | ||
| Q3 25 | $-43.8M | — | ||
| Q2 25 | $-41.4M | — | ||
| Q4 24 | $-31.8M | — | ||
| Q2 24 | — | $405.6K | ||
| Q1 24 | $-16.9M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | 61.1% | ||
| Q1 24 | — | — |
| Q4 25 | -2097.3% | — | ||
| Q3 25 | -3069.0% | — | ||
| Q2 25 | — | — | ||
| Q4 24 | -8344.1% | — | ||
| Q2 24 | — | -44.3% | ||
| Q1 24 | -4247.4% | — |
| Q4 25 | -1779.0% | — | ||
| Q3 25 | -2629.5% | — | ||
| Q2 25 | — | — | ||
| Q4 24 | -6973.7% | — | ||
| Q2 24 | — | 12.9% | ||
| Q1 24 | -3200.8% | — |
| Q4 25 | $-0.52 | — | ||
| Q3 25 | $-0.57 | — | ||
| Q2 25 | $-0.54 | — | ||
| Q4 24 | $-0.47 | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-0.36 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $742.2M | $8.5M |
| Total DebtLower is stronger | — | $2.3M |
| Stockholders' EquityBook value | $752.6M | — |
| Total Assets | $791.6M | $15.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $742.2M | — | ||
| Q3 25 | $680.3M | — | ||
| Q2 25 | $661.1M | — | ||
| Q4 24 | $742.0M | — | ||
| Q2 24 | — | $8.5M | ||
| Q1 24 | $566.5M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | $2.3M | ||
| Q1 24 | — | — |
| Q4 25 | $752.6M | — | ||
| Q3 25 | $687.6M | — | ||
| Q2 25 | $670.4M | — | ||
| Q4 24 | $733.4M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $568.9M | — |
| Q4 25 | $791.6M | — | ||
| Q3 25 | $729.9M | — | ||
| Q2 25 | $701.4M | — | ||
| Q4 24 | $754.8M | — | ||
| Q2 24 | — | $15.9M | ||
| Q1 24 | $579.1M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-36.2M | — |
| Free Cash FlowOCF − Capex | $-36.2M | — |
| FCF MarginFCF / Revenue | -1560.0% | — |
| Capex IntensityCapex / Revenue | 0.3% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-124.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-36.2M | — | ||
| Q3 25 | $-38.9M | — | ||
| Q2 25 | $-28.0M | — | ||
| Q4 24 | $-20.7M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-26.0M | — |
| Q4 25 | $-36.2M | — | ||
| Q3 25 | $-39.0M | — | ||
| Q2 25 | $-28.0M | — | ||
| Q4 24 | $-20.9M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-26.0M | — |
| Q4 25 | -1560.0% | — | ||
| Q3 25 | -2340.4% | — | ||
| Q2 25 | — | — | ||
| Q4 24 | -4577.0% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -4919.5% | — |
| Q4 25 | 0.3% | — | ||
| Q3 25 | 5.8% | — | ||
| Q2 25 | — | — | ||
| Q4 24 | 45.8% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 2.3% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
